The effect of VMP35 supplement ingredients encapsulated in a novel phospholipid prodosome SK713 SLP nutrient delivery technology observed as a result of changes in properties of live human blood

Background: In North America digestive malfunction in terms of disintegration, dissolution, and absorption of food and nutrients, is a widespread malady. Malabsorption is also an exacerbating factor in most chronic degenerative diseases that might benefit from dietary supplementation. The purpose of this experiment was to evaluate absorption following the sublingual administration of VMP35 SK713 encapsulated nutraceutical formulation. Method: Changes in peripheral blood smears from 38 subjects were observed using peripheral live blood cell imaging (LBCI) with phase contrast microscopy. Observation of changes in properties of live blood was made and compared to placebo and baseline at five and 30 minutes after administration. Results: Compared to baseline and control, the VMP35 formulation SK713 SLP technology effected positive changes in the blood. They were demonstrated by morphological, hematological and rheological changes observed five minutes from the intake and were sustained for at least 30 minutes post intake. Conclusions: These observable changes showed that the SK713 SLP system can make a key contribution to increasing the potential benefits of dietary supplementation for those patients with compromised digestive processes. We encourage additional research on the effects of this novel neutraceutical formulation and delivery system.